Fresenius Medical Care North America

Retia Medical, LLC is a medical device company based in East Lansing, Michigan, focused on developing innovative monitoring solutions for high-risk patients. The company specializes in hemodynamic monitors that assess critical health metrics, particularly cardiac output, which indicates the rate of blood flow from the heart. These devices are designed to support clinicians in detecting, diagnosing, and treating life-threatening conditions during high-risk surgeries, such as cardiac, neuro, transplant, and gastrointestinal procedures. Retia Medical's technology is applicable in various healthcare settings, including intensive care units, operating rooms, and potentially emergency departments or home care. By utilizing advanced algorithms, its monitoring systems provide accurate data on blood flow, enabling healthcare providers to make informed decisions that enhance patient care for conditions like sepsis, heart failure, and multi-organ failure. The company aims to seek FDA approval for its products, which are backed by extensive validation through animal and human studies and support from industry experts.

BioIntelliSense is a health technology company that provides continuous remote health monitoring through a medical-grade wearable data platform. Its Data-as-a-Service offering collects multi-parameter vital signs, physiological biometrics, and symptomatic events via devices such as BioButton and BioSticker, enabling remote monitoring, early detection, and clinical insights. The FDA-cleared BioButton and BioSticker devices facilitate monitoring and data-driven care. The platform delivers high-resolution patient trending and reporting to support decision-making across care settings, from hospital to home. The devices monitor metrics including skin temperature, resting heart rate, resting respiratory rate, gait, body position, activity, falls, sleep, and symptom patterns such as coughing and sneezing. The solution aims to improve patient outcomes, streamline clinical workflows, and reduce hospital readmissions through continuous screening and predictive analytics.

InterWell Health is a national partnership focused on nephrological healthcare services, integrating a diverse range of expert nephrology practices with the resources of Fresenius Medical Care North America. The organization aims to innovate care for kidney patients by managing them under at-risk arrangements with various public and private payors. InterWell Health addresses the full continuum of chronic kidney disease, transplant, end-stage renal disease, and conservative care. By advancing value-based contracting models, the company strives to enhance clinical outcomes while reducing costs, ultimately improving the quality of life for renal patients and making care more attractive to medical professionals and payors alike.

BioIntelliSense is a health technology company that provides continuous remote health monitoring through a medical-grade wearable data platform. Its Data-as-a-Service offering collects multi-parameter vital signs, physiological biometrics, and symptomatic events via devices such as BioButton and BioSticker, enabling remote monitoring, early detection, and clinical insights. The FDA-cleared BioButton and BioSticker devices facilitate monitoring and data-driven care. The platform delivers high-resolution patient trending and reporting to support decision-making across care settings, from hospital to home. The devices monitor metrics including skin temperature, resting heart rate, resting respiratory rate, gait, body position, activity, falls, sleep, and symptom patterns such as coughing and sneezing. The solution aims to improve patient outcomes, streamline clinical workflows, and reduce hospital readmissions through continuous screening and predictive analytics.